Head to Head Survey: Tonix Pharmaceuticals (TNXP) vs. Its Competitors

Tonix Pharmaceuticals (NASDAQ:TNXP) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Tonix Pharmaceuticals to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.

Risk and Volatility

Tonix Pharmaceuticals has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals’ rivals have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Tonix Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1	0	1	2	3.00
Tonix Pharmaceuticals Competitors	9869	15283	45611	1598	2.54

Tonix Pharmaceuticals presently has a consensus target price of $22.33, suggesting a potential upside of 550.17%. As a group, “Biotechnology” companies have a potential upside of 123.19%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Tonix Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Tonix Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-420.45%	-78.17%	-68.80%
Tonix Pharmaceuticals Competitors	-12,323.33%	-195.38%	-30.39%

Insider & Institutional Ownership

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Tonix Pharmaceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11 million	-$124.02 million	-0.27
Tonix Pharmaceuticals Competitors	$756.66 million	$13.58 million	-18.96

Tonix Pharmaceuticals’ rivals have higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Tonix Pharmaceuticals beats its rivals on 8 of the 13 factors compared.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving the central nervous system, immunology and infectious diseases. The company’s research programs are designed to address disorders with significant unmet medical needs, including chronic pain, neuropsychiatric conditions and infectious diseases. Tonix’s pipeline has included TNX-102 SL, an investigational sublingual formulation of cyclobenzaprine being studied for fibromyalgia and other pain-related conditions.